GRADE evidence table
| Quality assessment . | Summary of findings . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of participants (studies) . | Risk bias . | Inconsistency . | Indirectness . | Imprecision . | Publication bias . | Overall quality of evidence . | Study event rates (%) . | RE (95% CI) . | Anticipated absolute effects . | ||
| Temporary cessation of VKA alone . | Temporary cessation of VKA + vitamin K administration . | Risk with temporary cessation of VKA alone . | Risk difference with temporary cessation of VKA + vitamin K administration (range) . | ||||||||
| Mortality (follow-up: 30-90 d; assessed with all-cause mortality) | |||||||||||
| 860 (3 RCTs) | NS | NS | NS | S* | None | ⊕⊕⊕○ Moderate | 13/439 (3.0) | 16/421 (3.8) | RR = 1.24 (0.62-2.47) | 30 per 1000 | 7 more per 1000 (11 fewer-44 more) |
| Major bleeding (follow-up: mean, 90 d; assessed with fatal bleeding or bleeding requiring blood transfusion or admission) | |||||||||||
| 801 (2 RCTs) | NS | NS | NS | S* | None | ⊕⊕⊕○ Moderate | 4/409 (1.0) | 10/392 (2.6) | RR = 2.43 (0.81-7.27) | 10 per 1000 | 14 more per 1000 (2 fewer-61 more) |
| Any thromboembolism (follow-up: mean, 90 d; assessed with venous or arterial thromboembolism) | |||||||||||
| 801 (2 RCTs) | NS | NS | NS | S* | None | ⊕⊕⊕○ Moderate | 4/409 (1.0) | 5/392 (1.3) | RR = 1.29 (0.35-4.78) | 10 per 1000 | 3 more per 1000 (6 fewer-37 more) |
| Proportion reaching goal INR (follow-up: mean, 1 d; assessed with INR goal ranges: INR, 1.8-3.2; INR, 2.3-4.5; and INR, 2.0-4.0) | |||||||||||
| 1025 (5 RCTs) | S† | S‡ | NS | S* | None | ⊕○○○ Very low | 90/518 (17.4) | 218/507 (43.0) | RR = 1.95 (0.88-4.33) | 174 per 1000 | 165 more per 1000 (21 fewer-579 more) |
| Quality assessment . | Summary of findings . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of participants (studies) . | Risk bias . | Inconsistency . | Indirectness . | Imprecision . | Publication bias . | Overall quality of evidence . | Study event rates (%) . | RE (95% CI) . | Anticipated absolute effects . | ||
| Temporary cessation of VKA alone . | Temporary cessation of VKA + vitamin K administration . | Risk with temporary cessation of VKA alone . | Risk difference with temporary cessation of VKA + vitamin K administration (range) . | ||||||||
| Mortality (follow-up: 30-90 d; assessed with all-cause mortality) | |||||||||||
| 860 (3 RCTs) | NS | NS | NS | S* | None | ⊕⊕⊕○ Moderate | 13/439 (3.0) | 16/421 (3.8) | RR = 1.24 (0.62-2.47) | 30 per 1000 | 7 more per 1000 (11 fewer-44 more) |
| Major bleeding (follow-up: mean, 90 d; assessed with fatal bleeding or bleeding requiring blood transfusion or admission) | |||||||||||
| 801 (2 RCTs) | NS | NS | NS | S* | None | ⊕⊕⊕○ Moderate | 4/409 (1.0) | 10/392 (2.6) | RR = 2.43 (0.81-7.27) | 10 per 1000 | 14 more per 1000 (2 fewer-61 more) |
| Any thromboembolism (follow-up: mean, 90 d; assessed with venous or arterial thromboembolism) | |||||||||||
| 801 (2 RCTs) | NS | NS | NS | S* | None | ⊕⊕⊕○ Moderate | 4/409 (1.0) | 5/392 (1.3) | RR = 1.29 (0.35-4.78) | 10 per 1000 | 3 more per 1000 (6 fewer-37 more) |
| Proportion reaching goal INR (follow-up: mean, 1 d; assessed with INR goal ranges: INR, 1.8-3.2; INR, 2.3-4.5; and INR, 2.0-4.0) | |||||||||||
| 1025 (5 RCTs) | S† | S‡ | NS | S* | None | ⊕○○○ Very low | 90/518 (17.4) | 218/507 (43.0) | RR = 1.95 (0.88-4.33) | 174 per 1000 | 165 more per 1000 (21 fewer-579 more) |